Adaptimmune Therapeutics plc has a powerful new partner in Roche Holding AG’s Genentech for its allogeneic T-cell therapy program, based on Adaptimmune’s induced pluripotent stem cell (iPSC)-derived platform. The deal gives the biotech a leg up in a race that has lately attracted a number of large biopharma industry players, but also marks a significant vote of confidence in Adaptimmune’s programs and for cell therapies in solid tumors overall.
Oxfordshire, UK-based Adaptimmune said 7 September that it had partnered with Genentech to develop and commercialize off-the-shelf therapies in up...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?